目的:探究CT影像组学对宫颈癌同步放化疗临床转归的预测价值。方法:回顾性分析南京医科大学附属常州二院2017年9月至2021年12月,经病理证实为宫颈癌并采用同步放化疗治疗的121例患者的CT影像和临床资料。其中,按照2.5∶1比例将患者分为训练组86例、验证组35例。对所有病灶进行肿瘤病灶感兴趣区(ROI)勾画,再从ROI中提取影像组学特征。随后采用最小冗余最大相关性(mRMR)和最小绝对收缩选择算子(LASSO)筛选最优的影像组学特征,计算影像组学分数,最终使用受试者工作特征(ROC)曲线评估模型的效能。结果:经mRMR与LASSO后筛选出3个影像组学特征用以建立影像组学评分。ROC曲线下面积训练组为0.85,验证组为0.85。结论:基于CT影像组学特征回归模型可用于预测宫颈癌同步放化疗临床转归。

[1] SANTORO A,ANGELICO G,INZANI F,et a l.Standard ultrastaging compared to one-step nucleic acid amplification(OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer[J].Int J Gynecol Cancer,2020,30(12):1871-1877.
[2] BHATLA N,AOKI D,SHARMA D N,et al.Cancer of the cervix uteri[J].Int J GynaecolObstet,2018,143(Suppl.3):22-36.
[3] ALMENDRO V,MARUSYK A,POLYAK K.Cellular heterogeneity and molecular evolution in Cancer[J].Annu Rev Pathol,2012,8(1):277-302.
[4] 刘静雯,任洪荣,周冲,等.盆腔活性骨髓与宫颈癌放疗血液学毒性的关系[J].中国辐射卫生,2020,29(6):696-699.
[5] LAMBIN P,RIOS-VELAZQUEZ E,LEIJENAAR R,et al.Radiomics:extracting more information from medical images using advanced feature analysis[J].Eur J Cancer,2012,48(4):441-446.
[6] ZHOU Y,SU G Y,HU H,et al.Radiomics analysis of dual energy CT-derived iodine maps for diagnosing metastatic cervical lymph nodes in patients with papillary thyroid cancer[J].EurRadiol,2020,30(11):6251-6262.
[7] AERTS H J,VELAZQUEZ E R,LEIJENAAR R T,et al.Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach[J].Nat Commun,2014,5(1):1-9.
[8] WANG J,KATO F,OYAMA-MANABE N,et al.Identifying triple negative breast cancer using background parenchymal enhancement heterogeneity on dynamic contrast-enhanced MRI:a pilot radiomics study[J].PLoS One,2015,10(11):e0143308.
[9] MARTH C,LANDONI F,MAHNER S,et al.Cervical cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2017,28:iv72-iv83.
[10] 王蒙,张蓓.术前同期放化疗治疗局部晚期宫颈癌的临床观察[J].东南大学学报(医学版),2013,32(6):713-717.
[11] KYUNG R H,SUN B J,KANG W D,et al.The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients[J].ObstetGynecol Sci,2015,58(5):368-376.
[12] USHIJIMA K,FUJIYOSHI K,KAWANO K,et al.Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer:a long-term follow-up study[J].J Gynecol Oncol,2013,24(2):108-113.
[13] BI W L,HOSNY A,SCHABATH M B,et al.Artificial intelligence in cancer imaging:clinical challenges and applications[J].CA Cancer J Clin,2019,69(2):127-157.
[14] ROSSI G,BARABINO E,FEDELI A,et al.Radiomic detection of EGFR mutations in NSCLC[J].Cancer Res,2021,81(3):724-731.
[15] KOYASU S,NISHIO M,ISODA H,et al.Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on ¹⁸F FDG-PET/CT[J].Ann Nucl Med,2020,34(1):49-57.
[16] CHEN A,LU L,PU X,et al.CT-based radiomics model for predicting brain metastasis in category T1 lung adenocarcinoma[J].AJR Am J Roentgenol,2019,213(1):134-139.
[17] SUN F,CHEN Y,CHEN X,et al.CT-based radiomics for predicting brain metastases as the first failure in patients with curatively resected locally advanced non-small cell lung cancer[J].Eur J Radiol,2021,134:109411.
[18] MU W,JIANG L,SHI Y,et al.Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images[J].J Immunother Cancer,2021,9(6):e002118.
[19] BLANC-DURAND P,CAMPEDEL L,MULE S,et al.Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer[J].Eur Radiol,2020,30(6):3528-3537.
[20] YANG F,YOUNG L,GRIGSBY P.Predictive value of standardized intratumoral metabolic heterogeneity in locally advanced cervical cancer treated with chemoradiation[J].Int J Gynecol Cancer,2016,26(4):777-784.
[21] FANG M,KAN Y,DONG D,et al.Multi-habitat based radiomics for the prediction of treatment response to concurrent chemotherapy and radiation therapy in locally advanced cervical cancer[J].Front Oncol,2020,10:563.
[22] AYDOS U,SEVER T,VURAL O,et al.Prognostic value of fluorodeoxyglucose positron emission tomography derived metabolic parameters and textural features in pediatric sarcoma[J].Nucl Med Commun,2022,43(7):778-786.
[23] KANG J,LEE J H,LEE H S,et al.Radiomics features of(18) F-fluorodeoxyglucose positron-emission tomography as a novel prognostic signature in colorectal cancer[J].Cancers(Basel),2021,13(3):392.
[24] DONG D,ZHANG F,ZHONG L Z,et al.Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer:a randomized controlled trial substudy(NCT01245959)[J].BMC Med,2019,17(1):1-11.